A Follow-Up Study of 85 Patients with Graves’ Disease in Remission Who Developed Undetectahle Serum Thyroid-Stimulating Hormone Concentrations Using Sensitive TSH Assays

1991 ◽  
Vol 35 (5) ◽  
pp. 185-189 ◽  
Author(s):  
Keisuke Nagai ◽  
Hajime Tamai ◽  
Toshio Mukuta ◽  
Tetsuya Morita ◽  
Sunao Matsubayashi ◽  
...  
Keyword(s):  
Thyroid Stimulating Hormone ◽  
Follow Up Study ◽  
Stimulating Hormone

scholarly journals THE EFFECT OF BETA-BLOCKERS ON A COURSE OF CHRONIC HEART FAILURE IN PATIENTS WITH A LOW TRIIODOTHYRONINE SYNDROME

2020 ◽  
Vol 73 (7) ◽  
pp. 1402-1409
Author(s):  
Sergiy M. Pyvovar ◽  
Iurii S. Rudyk ◽  
Mykola P. Kopytsya ◽  
Tetiana V. Lozyk ◽  
Valentina Ir. Galchinskaya ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Opposite Effect ◽  
Beta Blockers ◽  
Thyroid Stimulating Hormone ◽  
Functional Class ◽  
Left Heart ◽  
Follow Up Study ◽  
Serum T3

The aim: The aim is to study the effect of β-ABs in patients with LT3S on the course of HF. Materials and methods: 354 patients with HF on a background of post-infarction cardiosclerosis were included in the 2-yeared follow-up study. LT3S was diagnosed at 89 (25.1%) patients. The levels of thyroid-stimulating hormone, free T3f and T4f, and reversible T3 were determined. The echocardioscopy was performed. Results: Patients with HF in combination with LT3S have a heavier functional class by NYHA, greater dilatation of the left heart cavities, less myocardial contractility, a higher frequency of atrial fibrillation and re-hospitalization. The use of β-ABs in patients with HF without LT3S leads to a likely decrease in hospitalization frequency, while in patients with LT3S it has an opposite effect. The frequency of rehospitalization increases with an excess of β-ABs dose > 5 mg (equivalent to bisoprolol). At these patients a decrease in serum T3 level and negative dynamics of parameters of intracardiac hemodynamics are observed. Conclusions: The use of β-ABs in patients with LT3S leads to an increase in re-hospitalization at a dose over 5.0 mg (equivalent to bisoprolol). In these patients there is a decrease in serum T3, an increase in T4 level; and the ejection fraction decrease; and heart cavities size increase.

scholarly journals A raised thyroid stimulating hormone result - a 12-month follow-up study in general practice

2010 ◽  
Vol 2 (1) ◽  
pp. 29 ◽  
Author(s):  
Veronique Gibbons ◽  
John Conaglen ◽  
Ross Lawrenson
Keyword(s):  
General Practice ◽  
Quantitative Research ◽  
Best Practice ◽  
Adult Population ◽  
Laboratory Data ◽  
Reference Interval ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Function Tests ◽  
Stimulating Hormone

INTRODUCTION: Subclinical hypothyroidism (SCH) is common in older patients. AIM: To review the management of patients identified with a raised thyroid stimulating hormone (TSH) result in a 12-month period and compare this to current guidelines from the New Zealand Best Practice Advocacy Centre (BPAC). METHODS: We collected laboratory data on thyroid function tests (TFTs) that were reported between December 2005 and November 2006 from two general practices with an adult population of approximately 21 000. Data were collected on symptoms, investigations, thyroid medication, family history and comorbidities. We used chi-squared tests to compare findings by age, gender and ethnicity. RESULTS: Older women of European descent were more likely to be to have initial results suggesting SCH. The number of follow-up tests ranged from 0 to 5 tests in a 12-month period. Forty-eight percent of individuals did not have any follow-up investigations. Seventy-three percent of FT4 tests taken are requested concurrently with TSH. Of those who had a repeat TSH test, just over 40% had a result within the reference interval. Twenty-eight percent had two TSH results consistent with SCH. Thirty-five percent of patients with antibody results were positive. The most commonly-recorded symptoms were tiredness and weight gain. DISCUSSION: We found inconsistencies in the management of SCH which were not related to patient characteristics such as age, gender or ethnicity. Further research is needed to determine if SCH is associated with increased morbidity and to provide a clear rationale for management of patients with SCH. KEYWORDS: Hypothyroidism; family practice; quantitative research; general practice

scholarly journals Central TSH Dysregulation in a Patient with Familial Non-Autoimmune Autosomal Dominant Hyperthyroidism Due to a Novel Thyroid-Stimulating Hormone Receptor Disease-Causing Variant

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 196
Author(s):  
Jasna Suput Omladic ◽  
Maja Pajek ◽  
Urh Groselj ◽  
Katarina Trebusak Podkrajsek ◽  
Magdalena Avbelj Stefanija ◽  
...  
Keyword(s):  
Hormone Receptor ◽  
Autosomal Dominant ◽  
Signs And Symptoms ◽  
Thyroid Stimulating Hormone ◽  
Ablation Therapy ◽  
Tsh Secretion ◽  
Tshr Gene ◽  
Adult Male Patient ◽  
Stimulating Hormone

Background and Objectives. Familial non-autoimmune autosomal dominant hyperthyroidism (FNAH) is a rare cause of childhood hyperthyroidism. It is caused by the thyroid-stimulating hormone receptor (TSHR) gene variants. So far, only around 40 families with FNAH have been reported. Patients with activating TSHR variants demonstrated the same classical signs and symptoms of hyperthyroidism as seen in patients with Graves’ disease. Since 2012, ablative therapy is recommended to avoid relapses of hyperthyroidism and its consequences. Case Presentation. We presented a young adult male patient with a novel heterozygous TSHR disease-causing variant p.Arg418Lys (c.1253G>A) in the exon 10, who presented with a mild but progressive FNAH, with a follow-up since infancy. Discussion. Constantly suppressed TSH, including during the euthyreosis in childhood and hypothyreosis after iodine ablation therapy, suggested central dysregulation of the TSH secretion.

scholarly journals Transient high thyroid stimulating hormone and hypothyroidism incidence during follow up of subclinical hypothyroidism

2021 ◽  
Vol 55 (4) ◽  
pp. 204-214
Author(s):  
Munir Abu-Helalah ◽  
Hussam Ahmad Alshraideh ◽  
Sameeh Abdulkareem Al-Sarayreh ◽  
AbdelFattah Al-Hader
Keyword(s):  
Subclinical Hypothyroidism ◽  
Screening Program ◽  
Thyroid Stimulating Hormone ◽  
Overt Hypothyroidism ◽  
Thyroid Peroxidase ◽  
Free Triiodothyronine ◽  
High Prevalence ◽  
Levothyroxine Replacement ◽  
Stimulating Hormone

Abstract Objectives. Given the high prevalence of subclinical hypothyroidism (SCH), defined as high thyroid stimulating hormone (TSH) and normal free thyroxine (FT4), and uncertainty on treatment, one of the major challenges in clinical practice is whether to initiate the treatment for SCH or to keep the patients under surveillance. There is no published study that has identified predictors of short-term changes in thyroid status amongst patients with mild elevation of TSH (4.5–10 mIU/L). Subjects and Results. A cohort study was conducted on patients with SCH detected through a general population screening program, who were followed for six months. This project identified factors predicting progression to hypothyroid status, persistent SCH and transient cases. A total of 656 participants joined the study (431 controls and 225 were patients with SCH). A part of participants (12.2%) developed biochemical hypothyroidism during the follow-up, while 73.8% of the subjects became euthyroid and the remained ones (13.4%) stayed in the SCH status. The incidence of overt hypothyroidism for participants with TSH above 6.9 mIU/L was 36.7%, with incidence of 42.3% for females. Anti-thyroid peroxidase antibodies (TPO) positivity is an important predictor of development of hypothyroidism; however, it could be also positive due to transient thyroiditis. Conclusions. It can be concluded that females with TSH above 6.9 mIU/L, particularly those with free triiodothyronine (FT3) and FT4 in the lower half of the reference range, are more likely to develop biochemical hypothyroidism. Therefore, it is recommended to give them a trial of levothyroxine replacement. It is also recommended to repeat TSH after six months for male subjects and participants with baseline TSH equal or less than 6.9 mIU/L.

Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution

2009 ◽  
Vol 39 (3) ◽  
pp. 156-163 ◽  
Author(s):  
R. Wong ◽  
D. J. Topliss ◽  
L. A. Bach ◽  
P. S. Hamblin ◽  
V. Kalff ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Stimulating Hormone ◽  
Human Thyroid ◽  
Single Institution ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document